OncoQR ML GmbH logo

OncoQR ML GmbH

OncoQR ML OG is a biotech start-up, which develops novel therapeutic vaccines to cure cancer. OncoQRs vaccines are directed against solid tumours and can be regarded as a more potent alternative to monoclonal antibodies.

OncoQR was co-founded by Dr. Geert C. Mudde, Inventor of the S-TIR_ technology platform and is also Founder and CSO of U.K based TYG oncology and S-TARget Therapeutics. OncoQR utilizes S-TARgets S-TIR Technology Platform for the development of oncology based immunotherapies and was founded as a spin-off of S-TARget therapeutics GmbH. OncoQR ML obtained an exclusive license for the use af the S-TIR technology platform in oncology, infectious diseases and autoimmune disease; S-TARget continues developing vaccines for severe allergic diseases in collaboration with Allergopharma/Merck Seronon.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://oncoqr.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Mooslackengasse 17A-1190
Vienna
Austria
Email
Contact Number
+43 1 230 60 3700

OncoQRs first product TYG100 (formerly OQR100), in development by TYG Oncology Ltd. and CR-UK, targets pancreatic and other gastrointestinal cancers by inducing neutralizing antibodies against little gastrin (G17), a major growth factor for these forms of cancer.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/oncoqr-ml-gmbh” connections=”true” suffix=””]

In Dec. 2014, OncoQR received the funding from the FFG (the Austrian Research Promotion Agency) and ZIT (the Vienna Business Agency) for the further development of its reversible cancer immunotherapy treatments.